Last reviewed · How we verify
Antabuse (DISULFIRAM)
Antabuse (Disulfiram) is a small molecule aldehyde dehydrogenase inhibitor, originally developed and currently owned by Teva Women's, that targets lysyl oxidase homolog 4. It was FDA-approved in 1951 for the treatment of alcoholism. As an off-patent medication, it is available from multiple generic manufacturers. Key safety considerations include the risk of severe reactions when combined with alcohol. Antabuse works by inhibiting the enzyme responsible for breaking down acetaldehyde, a toxic byproduct of alcohol metabolism.
At a glance
| Generic name | DISULFIRAM |
|---|---|
| Sponsor | Teva Womens |
| Drug class | Aldehyde Dehydrogenase Inhibitor [EPC] |
| Target | Lysyl oxidase homolog 4 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1951 |
Approved indications
- Alcoholism
Common side effects
- Withdrawal of alcohol
- Psychoses
- Toxicity
Drug interactions
- CYP2E1 Substrates
- fosphenytoin
- metronidazole
- phenprocoumon
- phenytoin
- warfarin
Key clinical trials
- Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas (PHASE1)
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma (PHASE2)
- Anxiety During Abstinence in AUD (EARLY_PHASE1)
- Combining a Smartphone App With Medications to Manage Heavy Drinking (NA)
- The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration (PHASE1)
- Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer (PHASE2)
- Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform (PHASE2)
- Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antabuse CI brief — competitive landscape report
- Antabuse updates RSS · CI watch RSS